01. Executive Summary 02. List of Abbreviations 03. Introduction 04. Market Research Methodology Market Research Process Research Design Research Methodology 05. Scope of the Report Market Overview 06. Stem Cells 06.1 Autologous Cell Therapy 06.2 Allogenic Cell Therapy 07. Market Landscape 07.1 Global Stem Cell Anticancer Therapeutics Market Market Size and Forecast 07.2 Stem Cell Anticancer Therapeutics Market in the North America Market Size and Forecast 07.3 Stem Cell Anticancer Therapeutics Market in the Latin and South America Market Size and Forecast 07.4 Stem Cell Anticancer Therapeutics Market in Europe Market Size and Forecast 07.5 Stem Cell Anticancer Therapeutics Market in Asia Market Size and Forecast 07.6 Five Forces Analysis 08. Geographical Segmentation 09. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis 16.1 Roche Holding AG Business Overview Key Information SWOT Analysis 16.2 OncoMed Pharmaceuticals Inc. Business Overview Key Information SWOT Analysis 16.3 Celgene Corp. Business Overview Key Information SWOT Analysis 16.4 Merck and Co. Inc. Business Overview Key Information SWOT Analysis 17. Other Reports in this Series List of Exhibits Exhibit 1: Market Research Methodology Exhibit 2: Global Stem Cell Anticancer Therapeutics Market Segmentation Exhibit 3: Global Stem Cell Anticancer Therapeutics Market 2012-2016 (US$ million) Exhibit 4: Stem Cell Anticancer Therapeutics Market in the North America 2012-2016 (US$ million) Exhibit 5: Stem Cell Anticancer Therapeutics Market in the Latin and South America 2012-2016 (US$ million) Exhibit 6: Stem Cell Anticancer Therapeutics Market in Europe 2012-2016 (US$ million) Exhibit 7: Stem Cell Anticancer Therapeutics Market in Asia 2012-2016 (US$ million) Exhibit 8: Global Stem Cell Anticancer Therapeutics Market by Geographical Segmentation 2012 Exhibit 9: Business Segmentation of Roche Holding Ltd. Exhibit 10: Business Segmentation of Merck & Co. Inc.

Celgene Corp., Curis Inc., Exelixis Inc., Gamida Cell Ltd., Lonza Group, Merck & Co. Inc., OncoMed Pharmaceuticals Inc., Pfizer Inc., Roche Holding AG, Teva Pharmaceutical Industries Ltd., and Verastem Inc.